The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 29.1
Age-Adjusted and Age-Specific SEER Cancer Incidence Rates, 2012-2016 a
By International Classification of Childhood Cancer(ICCC)b Group and Subgroupc and Age at Diagnosis
Including myelodysplastic syndromes and Group III benign brain/CNS tumors
All Races, Males and Females
| ICCC Group and Subgroup | Ages 0-14 | Ages 0-19 | Ages <1 | Ages 1-4 | Ages 5-9 | Ages 10-14 | Ages 15-19 |
|---|---|---|---|---|---|---|---|
| All ICCC Groups Combined Excluding Group III benign brain/CNS tumors | 168.9 | 188.1 | 250.9 | 218.0 | 131.3 | 153.5 | 245.4 |
| All ICCC Groups Combined Including Group III benign brain/CNS tumors | 184.1 | 209.1 | 262.4 | 227.8 | 145.7 | 174.4 | 283.4 |
| I Leukemia (includes myelodysplastic syndromes) | 54.1 | 49.5 | 52.6 | 91.4 | 44.6 | 35.4 | 35.8 |
| I(a) Lymphoid leukemia | 41.1 | 35.4 | 19.7 | 76.3 | 36.7 | 22.9 | 18.3 |
| I(b) Acute myeloid leukemia | 7.9 | 8.3 | 18.2 | 10.4 | 4.2 | 7.8 | 9.6 |
| I(c) Chronic myeloproliferative diseases | 1.6 | 2.4 | 3.4 | 0.9 | 1.3 | 2.2 | 4.6 |
| I(d) Myelodysplastic syndrome and other myeloproliferative | 1.6 | 1.6 | 8.3 | 1.4 | 0.9 | 1.2 | 1.7 |
| I(e) Unspecified and other specified leukemias | 1.8 | 1.8 | 3.0 | 2.4 | 1.6 | 1.4 | 1.6 |
| II Lymphomas and reticuloendothelial neoplasms | 17.4 | 26.6 | 2.3 | 9.2 | 16.0 | 27.9 | 53.8 |
| II(a) Hodgkin lymphoma | 5.7 | 12.5 | - | 0.7 | 3.5 | 12.6 | 32.7 |
| II(b) Non-Hodgkin lymphoma (except Burkitt lymphoma) | 8.8 | 11.0 | - | 6.0 | 8.7 | 12.2 | 17.6 |
| II(c) Burkitt lymphoma | 2.6 | 2.6 | - | 2.1 | 3.5 | 2.5 | 2.6 |
| II(d) Miscellaneous lymphoreticular neoplasms | 0.2 | 0.2 | - | - | - | - | - |
| II(e) Unspecified lymphomas | 0.2 | 0.4 | - | - | - | - | 0.8 |
| III CNS and misc intracranial and intraspinal neoplasmsd | 49.5 | 52.4 | 43.5 | 52.2 | 49.4 | 48.6 | 61.3 |
| III(a) Ependymomas and choroid plexus tumor | 4.2 | 3.9 | 9.0 | 6.2 | 2.9 | 3.0 | 3.0 |
| III(b) Astrocytoma | 18.7 | 17.5 | 14.4 | 22.2 | 19.1 | 16.5 | 14.1 |
| III(c) Intracranial and intraspinal embryonal tumors | 7.1 | 5.9 | 10.4 | 9.9 | 7.6 | 3.8 | 2.5 |
| III(d) Other gliomas | 5.9 | 5.6 | - | 5.9 | 7.0 | 5.5 | 4.7 |
| III(e) Other specified intracranial/intraspinal neoplasms | 11.7 | 17.5 | 5.1 | 6.5 | 11.2 | 17.4 | 34.9 |
| III(f) Unspecified intracranial and intraspinal neoplasms | 1.9 | 2.0 | 2.7 | 1.6 | 1.6 | 2.3 | 2.2 |
| IV Neuroblastoma and other peripheral nervous cell tumor | 11.1 | 8.6 | 55.1 | 21.8 | 4.5 | 1.4 | 1.0 |
| IV(a) Neuroblastoma and ganglioneuroblastoma | 10.9 | 8.3 | 55.1 | 21.6 | 4.3 | 1.0 | 0.5 |
| IV(b) Other peripheral nervous cell tumors | 0.2 | 0.3 | - | - | - | - | 0.4 |
| V Retinoblastoma | 4.4 | 3.3 | 33.4 | 8.2 | 0.5 | - | - |
| VI Renal tumors | 8.7 | 7.1 | 17.5 | 19.0 | 6.2 | 1.7 | 2.3 |
| VI(a) Nephroblastoma and other nonepithelial renal tumor | 8.2 | 6.3 | 17.2 | 18.8 | 6.0 | 0.8 | - |
| VI(b) Renal carcinoma | 0.4 | 0.8 | - | - | - | 0.9 | 1.9 |
| VI(c) Unspecified malignant renal tumors | - | - | - | - | - | - | - |
| VII Hepatic tumors | 3.2 | 2.7 | 14.5 | 6.5 | 0.9 | 1.0 | 1.3 |
| VII(a) Hepatoblastoma | 2.8 | 2.1 | 14.5 | 6.4 | 0.5 | - | - |
| VII(b) Hepatic carcinoma | 0.4 | 0.6 | - | - | - | 0.8 | 1.3 |
| VII(c) Unspecified malignant hepatic tumors | - | - | - | - | - | - | - |
| VIII Malignant bone tumors | 7.9 | 9.8 | - | 1.9 | 6.6 | 15.2 | 15.5 |
| VIII(a) Osteosarcoma | 4.4 | 5.6 | - | - | 3.4 | 9.3 | 8.9 |
| VIII(b) Chrondosarcoma | 0.2 | 0.4 | - | - | - | 0.5 | 0.8 |
| VIII(c) Ewing tumor and related sarcomas of bone | 2.8 | 3.2 | - | 1.1 | 2.7 | 4.6 | 4.3 |
| VIII(d) Other specified malignant bone tumors | 0.4 | 0.5 | - | - | - | 0.7 | 0.9 |
| VIII(e) Unspecified malignant bone tumors | - | 0.2 | - | - | - | - | 0.5 |
| IX Soft tissue and other extraosseous sarcomas | 11.4 | 12.7 | 16.4 | 11.1 | 8.8 | 13.4 | 16.3 |
| IX(a) Rhabdomyosarcoma | 5.3 | 4.8 | 4.4 | 8.0 | 4.5 | 4.2 | 3.3 |
| IX(b) Fibrosarcoma, peripheral nerve & other fibrous | 1.0 | 1.3 | 4.1 | - | 0.8 | 1.1 | 1.9 |
| IX(c) Kaposi sarcoma | - | - | - | - | - | - | - |
| IX(d) Other specified soft tissue sarcomas | 3.9 | 5.1 | 5.7 | 1.9 | 2.7 | 6.1 | 8.9 |
| IX(e) Unspecified soft-tissue sarcomas | 1.2 | 1.5 | - | 0.6 | 0.8 | 1.9 | 2.2 |
| X Germ cell & trophoblastic tumors & neoplasms of gonads | 5.9 | 12.2 | 20.8 | 3.5 | 2.5 | 8.2 | 31.0 |
| X(a) Intracranial and intraspinal germ-cell tumors | 2.3 | 2.5 | 4.8 | 1.3 | 1.6 | 3.3 | 3.3 |
| X(b) Extracranial & extragonadal germ cell tumors | 1.5 | 1.6 | 15.0 | 1.5 | - | - | 1.7 |
| X(c) Malignant gonadal germ cell tumors | 2.5 | 7.9 | 3.3 | 1.5 | 1.2 | 4.5 | 23.8 |
| X(d) Gonadal carcinomas | - | 0.5 | - | - | - | - | 1.7 |
| X(e) Other and unspecified malignant gonadal tumors | - | 0.3 | - | - | - | - | 0.9 |
| XI Other malignant epithelial neoplasms and melanomase | 9.8 | 23.5 | 3.4 | 1.9 | 5.6 | 21.1 | 64.2 |
| XI(a) Adrenocortical carcinoma | 0.2 | 0.2 | - | - | - | - | - |
| XI(b) Thyroid carcinoma | 3.9 | 11.4 | - | - | 1.6 | 9.4 | 34.0 |
| XI(c) Nasopharyngeal carcinoma | 0.2 | 0.5 | - | - | - | 0.6 | 1.1 |
| XI(d) Malignant melanoma | 2.1 | 4.0 | - | 1.2 | 1.9 | 3.2 | 9.8 |
| XI(e) Skin carcinoma | - | 0.1 | - | - | - | - | - |
| XI(f) Other and unspecified carcinomase | 3.3 | 7.2 | - | - | 1.8 | 7.6 | 18.7 |
| XII Other and unspecified malignant neoplasms | 0.7 | 0.7 | 2.5 | 1.0 | - | 0.5 | 1.0 |
| XII(a) Other specified malignant tumors | 0.4 | 0.5 | - | 0.9 | - | - | 0.5 |
| XII(b) Other unspecified malignant tumors | 0.2 | 0.3 | - | - | - | - | 0.5 |
| Not classified by ICCC | 0.2 | 0.3 | - | - | - | - | - |
Footnotes:
a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
b International Classification of Childhood Cancer is based on ICD-O-3. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer. April 1, 2005: Vol 103, No. 7 , pg 1457-1467.
c Classifications are shown for invasive cases only except as noted. For ICCC groups and subgroups that include in situ behavior, only invasive cases are shown except as noted.
d Group III and Group III subgroups include benign brain/CNS tumors.
e Includes in situ urinary bladder tumors.
Rates are per 1,000,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.